Focus on JAK-1 inhibitors
In just 75 minutes, bring yourself up to speed on new advances in therapies for rheumatoid arthritis, with a focus on JAK-1 inhibitors.
Janus kinase (JAK-1) inhibitors belong to a class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic options of rheumatoid arthritis and other immune-mediated diseases.
Stay engaged in the material thanks to an innovative video format and interactive questions throughout.
At the end of this program, participants will be able to:
- Recognize unmet needs through the review of rheumatoid arthritis (RA) treatment landscape.
- Discuss the role of Janus Kinase (JAK) inhibitors in the management of rheumatoid arthritis through a better understanding of their pharmacology.
- Apply knowledge on expected efficacy and of potential side effects to counsel patients and monitor therapy on newly available targeted synthetic therapy upadacitinib.
This program is CCCEP accredited for 1.25 CEU.
- CCCEP Number: 1549-2020-2992-I-P, expires July 22, 2021.
- Presenters: Michael Boivin, BSc, Bsc Phm, RPh and Aaron Sihota, BSc, BSc Pharm, RPh